Summary Basis for Regulatory Action Date: [removed]From: Irwin M. Feuerstein, M.D., M.S., M.B.A., Chair of the BLA BLA STN - Von Willebrand factor - Document - PDFSEARCH.IO

First Page		Document Content
Hematology Clinical research Design of experiments Moroctocog alfa Factor VII Clinical trial Desmopressin Von Willebrand disease Drotrecogin alfa Medicine Haemophilia Health		Summary Basis for Regulatory Action Date: [removed]From: Irwin M. Feuerstein, M.D., M.S., M.B.A., Chair of the BLA BLA/STN#: [removed]Applicant Name: Pfizer Incorporated / Wyeth Biopharma Division of Wyeth Pharmaceu Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 582,59 KB Share Document on Facebook

	Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy DocID: 1eeTP - View Document
	scottish intensive care society annual report editorial DocID: 1avUR - View Document
	The STOP Sepsis Bundle Toolkit Strategies to Timely Obviate the Progression of Sepsis Department of Emergency Medicine Division of Pulmonary and Critical Care Medicine Department of Anesthesiology and Surgical Intensive DocID: 195mX - View Document
	The 8th Joint Scientific Congress of the KSCCM and JSICM Date ： February 15 , 2008 Venue DocID: 15XV5 - View Document
	Vincent and Moreno Critical Care 2010, 14:207 http://ccforum.com/contentREVIEW Clinical review: Scoring systems in the critically ill DocID: 12BBQ - View Document